|
Image-guided ultrasound ablation for precision targeting of prostate cancer
|
1R01CA230323-01
|
$580,217
|
$580,217
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$145,846
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Optimization of Non-Ablative Focused Ultrasound Therapy for Tumor Immunity
|
5F30CA200411-05
|
$49,524
|
$49,524
|
SKALINA, KARIN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Contributions of sympathetic signals to prostate cancer progression.
|
5F30CA203446-03
|
$49,524
|
$49,524
|
ZAHALKA, ALI
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-03
|
$382,013
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
$394,554
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
ARF1 signaling in prostate cancer
|
5R56CA204315-02
|
$243,960
|
$243,960
|
WU, GUANGYU
|
AUGUSTA UNIVERSITY
|
|
Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in Cancer
|
1U54CA233223-01
|
$6,353,982
|
$2,541,593
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$1,189
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$2,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$1,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$32,031
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
|
1R01CA221946-01
|
$488,881
|
$244,441
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
$76,296
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$25,950
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$1,313
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Androgen Signaling in prostate cancer progression and CRPC development
|
5R01CA070297-20
|
$305,119
|
$305,119
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-06
|
$368,984
|
$368,984
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Multifunctional immunoPET tracers for pancreatic and prostate cancer
|
7R01CA174294-06
|
$377,890
|
$188,945
|
WU, ANNA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
SOX9 Mediation of AR and ERG Driven Prostate Cancer
|
5R01CA168393-05
|
$361,050
|
$361,050
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Tumor Suppressive Pathways for Cancer Therapy
|
5R35CA197529-04
|
$1,044,000
|
$522,000
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterizing the signaling pathways that regulate Skp2 oncogenic function
|
5R01CA200573-03
|
$395,738
|
$395,738
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Elucidating a Novel Mechanism for SPOP in Suppressing Prostate Tumorigenesis
|
5K99CA212292-02
|
$168,804
|
$168,804
|
ZHANG, JINFANG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor
|
5R01CA211646-02
|
$411,481
|
$411,481
|
ZETTER, BRUCE
|
BOSTON CHILDREN'S HOSPITAL
|
|
Gaining Metabolic Insight in Older Men undergoing Androgen Deprivation Therapy for Prostate Cancer
|
1R01CA226211-01A1
|
$485,064
|
$485,064
|
BASARIA, SHEHZAD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
$194,979
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
$60,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
$484,427
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Co-targeting oncogenic pathways in advanced prostate cancer
|
5R01CA198097-03
|
$381,212
|
$381,212
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion
|
4UH3CA213392-03
|
$75,000
|
$75,000
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
The VITamin D and OmegA-3 TriaL (VITAL)
|
5R01CA138962-10
|
$3,474,603
|
$1,146,619
|
MANSON, JOANN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer
|
1R37CA227190-01
|
$600,105
|
$600,105
|
PENNEY, KATHRYN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics
|
5R01CA105304-12
|
$264,812
|
$264,812
|
SADAR, MARIANNE
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Development of a PSMA-Targeted Small-Molecule Drug Conjugate for Prostate Cancer
|
1R43CA221511-01A1
|
$300,000
|
$300,000
|
LANGTON-WEBSTER, BEATRICE
|
CANCER TARGETED TECHNOLOGY, LLC
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
$676,554
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
$29,996
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
$5,760
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Nuclear Factor I/B Action in Castrate Resistant Prostate Cancer
|
5R00CA197315-05
|
$170,316
|
$170,316
|
GRABOWSKA, MAGDALENA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
MR Fingerprinting and Computerized Decision Support for Prostate Cancer
|
5R01CA208236-02
|
$636,773
|
$636,773
|
GULANI, VIKAS
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeted MRI contrast agents for differential diagnosis of prostate cancer
|
5R01CA211762-02
|
$424,315
|
$424,315
|
LU, ZHENG-RONG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
$89,047
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Pathology Image Informatics Platform for visualization, analysis and management
|
5U24CA199374-04
|
$573,677
|
$286,839
|
MADABHUSHI, ANANT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Small Molecule Activators of PP2A (SMAPs) for Prostate Cancer Therapy
|
5R01CA181654-04
|
$374,305
|
$374,305
|
NARLA, GOUTHAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging
|
5R01CA202814-03
|
$394,519
|
$394,519
|
STEINMETZ, NICOLE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
3P01CA098912-14S1
|
$18,678
|
$18,678
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
3P01CA098912-14S2
|
$12,477
|
$12,477
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
5P01CA098912-14
|
$1,636,904
|
$1,636,904
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary Malignancy
|
1K08CA230155-01
|
$183,258
|
$62,308
|
DASKIVICH, TIMOTHY
|
CEDARS-SINAI MEDICAL CENTER
|
|
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer
|
5R01CA218526-02
|
$384,283
|
$384,283
|
DI VIZIO, DOLORES
|
CEDARS-SINAI MEDICAL CENTER
|
Total relevant funding to Prostate for this search: $239,139,126
|